ARS Pharmaceuticals (SPRY) reported a Q1 net loss Wednesday of $0.35 per diluted share, wider than a loss of $0.11 a year earlier.
Analysts polled by FactSet expected a loss of $0.32.
Revenue for the quarter ended March 31 was $8 million.
Analysts surveyed by FactSet expected $7.5 million.
As of March 31, the company said it had $275.7 million in cash and cash equivalents on hand, and expected it could fund operations through the next three years.
ARS' shares were 1.1% higher in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。